All companies › RXST

RXST · RxSight, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells4
Research cases0
Last filing2026-09-02

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-02 — Kurtz Ronald M MD · sold 5,100 @ $6.96 2026-09-02 — Wilterding Mark · sold 7,765 @ $6.96 2026-09-02 — Goldshleger Ilya · sold 2,041 @ $6.96 2026-09-02 — Weinberg Eric · sold 2,041 @ $6.96
2026-09-022026-09-02

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Kurtz Ronald M MD Chief Medical Officer
Wilterding Mark Chief Financial Officer
Goldshleger Ilya Chief Operating Officer
Weinberg Eric See remarks
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $RXST is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-02', 'insider_name': 'Kurtz Ronald M MD', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 5100.0, 'price': 6.96, 'value': 35496.0, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Wilterding Mark', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 7765.0, 'price': 6.96, 'value': 54044.4, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Goldshleger Ilya', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 2041.0, 'price': 6.96, 'value': 14205.36, 'is_buy': False}, {'transaction_date': '2026-09-02', 'insider_name': 'Weinberg Eric', 'insider_title': 'See remarks', 'transaction_type': 'Open-market sell', 'shares': 2041.0, 'price': 6.96, 'value': 14205.36, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for RXST today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.